{"id":89763,"date":"2026-01-07T05:11:30","date_gmt":"2026-01-07T05:11:30","guid":{"rendered":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/dr-reddys-introduces-hevaxin-indias-inaugural-hepatitis-e-vaccine-approved-by-the-dcgi-specifically-designed-for-adult-use\/"},"modified":"2026-01-07T05:11:30","modified_gmt":"2026-01-07T05:11:30","slug":"dr-reddys-introduces-hevaxin-indias-inaugural-hepatitis-e-vaccine-approved-by-the-dcgi-specifically-designed-for-adult-use","status":"publish","type":"post","link":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/dr-reddys-introduces-hevaxin-indias-inaugural-hepatitis-e-vaccine-approved-by-the-dcgi-specifically-designed-for-adult-use\/","title":{"rendered":"Dr. Reddy&#8217;s introduces Hevaxin, India&#8217;s inaugural Hepatitis E vaccine approved by the DCGI, specifically designed for adult use."},"content":{"rendered":"<p>Dr. Reddy&#8217;s Laboratories has launched Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India. This vaccine is the only one approved by the Drug Controller General of India (DCGI) for active immunization against HEV infection in adults aged 18 to 65 years. Clinical studies have shown that Hevaxin provides long-lasting immunity and has a favorable safety and tolerability profile.<\/p>\n<p>Hepatitis E is a significant public health concern in India, causing a substantial proportion of acute viral hepatitis and acute liver failure cases. The World Health Organization (WHO) estimates that the infection affects around 20 million people globally each year, resulting in 3.4 million symptomatic cases, 70,000 deaths, and 3,000 stillbirths. In India, the disease burden is particularly high among vulnerable groups such as women of childbearing age, individuals with chronic liver disease, immunocompromised patients, and those preparing for organ transplantation.<\/p>\n<p>The launch of Hevaxin addresses a critical unmet need for patients at high risk of severe outcomes, including acute-on-chronic liver failure and high fatality rates. Dr. Reddy&#8217;s aims to provide a first-in-class preventive option and support the National Viral Hepatitis Control Programme, which seeks to reduce the morbidity and mortality associated with Hepatitis E in India. The company has partnered with Shenzhen Mellow Hope Pharm and Urihk Pharmaceutical for the marketing and distribution of Hevaxin in the domestic market.<\/p>\n<p>The launch of Hevaxin aligns with national efforts to reduce the burden of hepatitis A and E, as well as ambitious targets for hepatitis B and C elimination by 2030. According to M.V. Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy&#8217;s, the introduction of Hevaxin will provide a critical tool in the fight against Hepatitis E in India. With its favorable safety profile and long-lasting immunity, Hevaxin has the potential to make a significant impact on public health in India and support the country&#8217;s efforts to control and eliminate hepatitis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Reddy&#8217;s Laboratories has launched Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India. This vaccine is the only one approved by the Drug Controller General of India (DCGI) for active immunization against HEV infection in adults aged 18 to 65 years. Clinical studies have shown that Hevaxin [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":88041,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-89763","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dr-reddys"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89665,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/14\/the-u-s-fda-has-granted-approval-to-dr-reddys-a-leading-pharmaceutical-company-to-manufacture-and-distribute-a-treatment-for-gonorrhea\/","url_meta":{"origin":89763,"position":0},"title":"The U.S. FDA has granted approval to Dr. Reddy&#8217;s, a leading pharmaceutical company, to manufacture and distribute a treatment for gonorrhea.","author":"Team Small News","date":"December 14, 2025","format":false,"excerpt":"The US Food and Drug Administration (FDA) has approved two new oral medicines, Nuzolvence (zoliflodacin) and Blujepa (gepotidacin), to treat gonorrhea, a common sexually transmitted infection (STI) that is increasingly resistant to existing treatments. The World Health Organization (WHO) has classified the bacteria that causes gonorrhea, Neisseria gonorrhoeae, as a\u2026","rel":"","context":"In &quot;Dr Reddy's&quot;","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89802,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/dr-reddys-introduces-generic-version-of-antihistamine-eye-drops-to-the-us-market\/","url_meta":{"origin":89763,"position":1},"title":"Dr Reddy&#8217;s introduces generic version of antihistamine eye drops to the US market","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair, and dander.\u2026","rel":"","context":"In &quot;Dr Reddy's&quot;","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89794,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/13\/dr-reddys-laboratories-has-been-issued-a-pre-approval-inspection-letter-from-the-usfda-for-its-biologics-facility-located-in-hyderabad\/","url_meta":{"origin":89763,"position":2},"title":"Dr. Reddy&#8217;s Laboratories has been issued a pre-approval inspection letter from the USFDA for its biologics facility located in Hyderabad.","author":"Team Small News","date":"January 13, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards.\u2026","rel":"","context":"In &quot;Dr Reddy's&quot;","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89748,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/delhi-high-court-bars-dr-reddys-from-producing-venusia-sunscreens-bearing-the-sun-logo\/","url_meta":{"origin":89763,"position":3},"title":"Delhi High Court bars Dr Reddy&#8217;s from producing VENUSIA sunscreens bearing the SUN logo.","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"The Delhi High Court has issued an interim order restraining Dr. Reddy's Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word \"SUN\". The court's decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy's is infringing on its\u2026","rel":"","context":"In &quot;Glenmark&quot;","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89836,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/22\/dr-reddys-relies-on-biosimilars-and-weight-loss-medication-launches-to-compensate-for-declining-us-dominance-of-revlimid\/","url_meta":{"origin":89763,"position":4},"title":"Dr Reddy&#8217;s relies on biosimilars and weight-loss medication launches to compensate for declining US dominance of Revlimid.","author":"Team Small News","date":"January 22, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to\u2026","rel":"","context":"In &quot;Dr Reddy's&quot;","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89721,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/30\/delhi-high-court-prohibits-dr-reddys-from-using-the-sun-trademark-on-sunscreen-product-labels\/","url_meta":{"origin":89763,"position":5},"title":"Delhi High Court prohibits Dr. Reddy&#8217;s from using the &#8216;SUN&#8217; trademark on sunscreen product labels.","author":"Team Small News","date":"December 30, 2025","format":false,"excerpt":"The Delhi High Court has issued a restraining order against Dr. Reddy's Laboratories, preventing the company from using the 'SUN' mark on their sunscreen product labels. This decision comes after a lawsuit was filed by Sun Pharmaceutical Industries, which claimed that Dr. Reddy's was infringing on their trademark rights. Sun\u2026","rel":"","context":"In &quot;Dr Reddy's&quot;","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89763"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89763\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88041"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}